生物制药公司Gyre治疗公司首席执行官出售股份,因为股票的售出率上升了13.9%的后阳性评级。 CEO of Gyre Therapeutics, a biopharmaceutical firm, sold shares as stock climbed 13.9% post-positive rating.

Gyre治疗学CEO Songjiang Ma最近出售了2,000股股份,使其所有权减少了0.07%。 Gyre Therapeutics CEO Songjiang Ma recently sold 2,000 shares, reducing his ownership by 0.07%. 这家专注于开发用于治疗代谢性肝病的Hydronidone的生物制药公司, 获得了Noble Financial的"超越"评级. The biopharmaceutical company, focused on developing Hydronidone for treating metabolic liver diseases, received an "outperform" rating from Noble Financial. 根据诺贝尔金融公司的积极覆盖面和收入估计,股票价格在星期二上涨了13.9%,达到11.77美元。 The stock price rose 13.9% to $11.77 on Tuesday, following Noble Financial's positive coverage and earnings estimates.